ALX Oncology
ALXO | NASDAQ
$1.00
-$0.04 (-3.85%)
At close: Nov 16, 2026, 4:00 PM ET
$0.98
-$0.02 (-2.00%)
After-hours:
Nov 16, 2026, 7:30 PM ET
-3.85%
(1D)No price chart data available for 1D timeframe.
Rating
35.8
Fundamentals Weak
Market Sentiment Neutral
Moat None
Sector Rank #638/1021 (Top 62%)
Key Statistics
Market Data
Market Cap $138.28M
1D Range
0.91 1.07
52W Range
0.89 2.60
Valuation (TTM)
PE -0.88
PB 1.02
EV/EBITDA -0.12
Valuation (NTM)
Forward PE N/A
Forward PEG 0.01
Price Target $4.00
Cash Flow
FCF Yield -51.3%
SBC Adj. FCF Yield -58.8%
SBC Impact -14.7%
Margins
Gross Margin 0.0%
Operating Margin 0.0%
FCF Margin N/A
Growth (CAGR)
Revenue 3Y | 5Y N/A |
N/A
Dil EPS 3Y | 5Y 54.0% |
16.0%
FCF 3Y | 5Y 30.6% |
3.7%
Returns
ROA -50.3%
ROE -90.3%
ROIC -56.5%
Financial Health
Net Cash
$128.52M
Current Ratio 9.71
Interest Coverage -58.67
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company’s lead product candidate is Evorpacept, a CD...
Sector Healthcare
Industry Biotechnology
Employees 48
IPO Date Jul 17, 2020
Website www.alxoncology.com
Fiscal Year January - December
Latest News
No news articles available yet.
Analyst Summary
# of Analysts
2
Consensus
Buy
Price Target
$4.00
Upside
+300.00%
Buy (2)
Hold (0)
Sell (0)
Add to Watchlist
Select watchlists to add or remove ALXO